PURPOSE OF REVIEW: Update on humanized mouse models and their use in biomedical research. RECENT FINDINGS: The recent description of immunodeficient mice bearing a mutated IL-2 receptor gamma chain (IL2rgamma) facilitated greatly the engraftment and function of human hematolymphoid cells and other cells and tissues. These mice permit the development of human immune systems, including functional T and B cells, following engraftment of hematopoietic stem cells (HSCs). The engrafted functional human immune systems are capable of T and B cell-dependent immune responses, antibody production, antiviral responses, and allograft rejection. Immunodeficient IL2rgamma(null) mice also support heightened engraftment of primary human cancers and malignant progenitor cells, permitting in-vivo investigation of pathogenesis and function. In addition, human-specific infectious agents for which animal models were previously unavailable can now be studied in vivo using these new-generation humanized mice. SUMMARY: Immunodeficient mice bearing an IL2rgamma(null) mutated gene can be engrafted with functional human cells and tissues, including human immune systems, following engraftment with human hematolymphoid cells. These mice are now used as in-vivo models to study human hematopoiesis, immunity, regeneration, stem cell function, cancer, and human-specific infectious agents without putting patients at risk.
PURPOSE OF REVIEW: Update on humanized mouse models and their use in biomedical research. RECENT FINDINGS: The recent description of immunodeficientmice bearing a mutated IL-2 receptor gamma chain (IL2rgamma) facilitated greatly the engraftment and function of human hematolymphoid cells and other cells and tissues. These mice permit the development of human immune systems, including functional T and B cells, following engraftment of hematopoietic stem cells (HSCs). The engrafted functional human immune systems are capable of T and B cell-dependent immune responses, antibody production, antiviral responses, and allograft rejection. Immunodeficient IL2rgamma(null) mice also support heightened engraftment of primary humancancers and malignant progenitor cells, permitting in-vivo investigation of pathogenesis and function. In addition, human-specific infectious agents for which animal models were previously unavailable can now be studied in vivo using these new-generation humanized mice. SUMMARY:Immunodeficientmice bearing an IL2rgamma(null) mutated gene can be engrafted with functional human cells and tissues, including human immune systems, following engraftment with human hematolymphoid cells. These mice are now used as in-vivo models to study humanhematopoiesis, immunity, regeneration, stem cell function, cancer, and human-specific infectious agents without putting patients at risk.
Authors: O ter Brake; N Legrand; K J von Eije; M Centlivre; H Spits; K Weijer; B Blom; B Berkhout Journal: Gene Ther Date: 2008-07-31 Impact factor: 5.250
Authors: Beatriz M Carreno; Joel R Garbow; Grant R Kolar; Erin N Jackson; John A Engelbach; Michelle Becker-Hapak; Leonidas N Carayannopoulos; David Piwnica-Worms; Gerald P Linette Journal: Clin Cancer Res Date: 2009-05-15 Impact factor: 12.531
Authors: Nicolas Legrand; Alexander Ploss; Rudi Balling; Pablo D Becker; Chiara Borsotti; Nicolas Brezillon; Jennifer Debarry; Ype de Jong; Hongkui Deng; James P Di Santo; Stephanie Eisenbarth; Elizabeth Eynon; Richard A Flavell; Carlos A Guzman; Nicholas D Huntington; Dina Kremsdorf; Michael P Manns; Markus G Manz; Jean-Jacques Mention; Michael Ott; Chozhavendan Rathinam; Charles M Rice; Anthony Rongvaux; Sean Stevens; Hergen Spits; Hélène Strick-Marchand; Hitoshi Takizawa; Anja U van Lent; Chengyan Wang; Kees Weijer; Tim Willinger; Patrick Ziegler Journal: Cell Host Microbe Date: 2009-07-23 Impact factor: 21.023
Authors: Diana M Brainard; Edward Seung; Nicole Frahm; Annaiah Cariappa; Charles C Bailey; William K Hart; Hae-Sook Shin; Sarah F Brooks; Heather L Knight; Quentin Eichbaum; Yong-Guang Yang; Megan Sykes; Bruce D Walker; Gordon J Freeman; Shiv Pillai; Susan V Westmoreland; Christian Brander; Andrew D Luster; Andrew M Tager Journal: J Virol Date: 2009-05-06 Impact factor: 5.103
Authors: Till Strowig; Cagan Gurer; Alexander Ploss; Yi-Fang Liu; Frida Arrey; Junji Sashihara; Gloria Koo; Charles M Rice; James W Young; Amy Chadburn; Jeffrey I Cohen; Christian Münz Journal: J Exp Med Date: 2009-06-01 Impact factor: 14.307
Authors: Nicholas D Huntington; Nicolas Legrand; Nuno L Alves; Barbara Jaron; Kees Weijer; Ariane Plet; Erwan Corcuff; Erwan Mortier; Yannick Jacques; Hergen Spits; James P Di Santo Journal: J Exp Med Date: 2008-12-22 Impact factor: 14.307
Authors: Mark Wunderlich; Ryan A Brooks; Rushi Panchal; Garrett W Rhyasen; Gwenn Danet-Desnoyers; James C Mulloy Journal: Blood Date: 2014-04-28 Impact factor: 22.113